Hemogenyx Pharmaceuticals secures £709k of new investment
Portfolio Pulse from
Hemogenyx Pharmaceuticals has secured £709,200 in new investment to support its clinical trials for HG-CT-1, an experimental treatment for relapsed/refractory acute myeloid leukaemia.
March 11, 2025 | 8:00 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Hemogenyx Pharmaceuticals has received a significant investment of £709,200 to fund its clinical trials for HG-CT-1, a treatment for a challenging form of leukaemia.
The new investment directly supports Hemogenyx's clinical trials, which is a positive development for the company. This could lead to advancements in their product pipeline, potentially increasing investor confidence and stock value.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80